32 results about "Pharmaceutical Substances" patented technology

A series of amphiphilic polymer materials which take pulullan as a main chain and polyester as a branch chain are synthesized. By adopting a novel synthetic method, the synthetic time of the series of amphiphilic polymer materials is shortened to 5 minutes, so that the materials have a relatively high industrial value. The series of amphiphilic polymer materials have multi-aspect application values in the field of medicine transfer such as microsphere and nanoparticle reparations and the like as well as modification of other medicine transfer systems and the like. The series of amphiphilic polymer materials are used for preparing nanoparticles and microsphere conveying transfer medicine or modification medicine transfer carriers such as nanoparticles and microspheres so as to achieve the purpose of increasing the solubility and stability of medicines, improving the curative effect of the medicines and reducing the toxic and side effects of the medicines. The series of materials, which are used as the medicine transfer carriers or modification medicine transfer carriers, can be used for achieving the purpose of liver targeting delivery and temperature sensitive control released delivery at the same time.

The invention discloses a preparation method of a mesoporous silica in situ doped acrylic resin bone cement composite for enhancing durable release capacity of medicines. The preparation method comprises the steps of firstly, mixing an amino silicon dioxide nanometer material with bone cement liquid to obtain a mixture, mixing the mixture with a bone cement solidifying agent, and in the process ofa polyreaction, performing in-situ introduction of the mesoporous silica nanometer material containing medicines; and uniformly mixing a mesoporous silica material with the liquid agent, and besides,enabling amino and carboxyl in bone cement acrylic resin to form electrostatic interaction to realize uniform and stable distribution in the bone cement, and achieve the purpose of durable and uniform release of the medicines. The prepared composite is high in operability, self spaces can be used for efficiently loading the medicines, and unique 2-8-nm mesoporous bore diameter is designed to enable the medicines distributed in the deep layer of the bone cement to be slowly released to the outside of the cement, so that durable and efficient release of the medicines is realized, besides, the characteristic and the function of the bone cement can be individually improved, and the biocompatibility and the anti-infection characteristic of the bone cement can be improved.

The invention discloses a small micelle nano-drug and a preparation method and application thereof. A micromolecule drug and an amphiphilic polymer/targeted amphiphilic polymer are added into polycthylene glycol oilgomers to obtain a mixed solution, then the mixed solution is added into a buffer solution to obtain the small micelle nano-drug; and the molecular weight of the polycthylene glycol oilgomers is 200-600. The invention designs and prepares an efficient paclitaxel PTX-loaded micelle MPTX, a disulfide cross-linked micelle MPTX and three TNBC active targeting micelle nano-drug, the drug loading capacity is up to 23.1 wt.%, the particle size is less than 40 nm, and the micelle nano-drug has good stability and drug release performance of reduction response.

The invention discloses a compound clobetasol propionate nano-medicament of which the particle size is 1-100 nanometers. The medicament consists of the following components in percentage by weight: 10.0-50 percent of surfactant, 0-8 percent of cosurfactant, 0.5-20 percent of oil, 0.001-4.0 percent of amitraz, 0.001-4.0 percent of clobetasol propionate, 0.001-10 percent of terbinafine and the balance of distilled water, wherein the total percentage by weight of the components is 100 percent. The medicament has the effects of resisting bacteria, diminishing inflammation, relieving itching and pain, killing mites and treating fungal diseases, eczema and various types of dermatitis caused by fungi such as dermatophyte, microsporosis capitis, acrothesium floccosum, microzyme of monilia and chaff ringworm fungus, and the like. The medicament is a yellow or colorless clear transparent liquid and has the advantages of high stability, high wetting property, good transdermal effect, nontoxicity, non-irritation, high safety, easiness for preparing, low cost and convenience for popularizing.

The invention relates to novel calcium chelating peptide as well as a preparation method and an application thereof. According to the invention, an amino acid sequence of the calcium chelating peptideis YQEPVIAPKL. The calcium chelating peptide provided by the invention is safe and non-toxic, and has better physicochemical activity compared with a traditional calcium supplement, and the calcium chelating capability of the calcium chelating peptide reaches 28.4 mg/g; the collagen peptide can be supplemented while absorption and bioavailability of calcium in a human body are improved, absorption and transport of calcium in Caco-2 small intestinal epithelial cells can be promoted, and the collagen peptide can be used as a raw material for drug development and biological calcium supplement. According to the preparation method provided by the invention, the calcium chelating peptide is successfully obtained, fish product resources can be fully utilized, the operation is simple, and a new way is provided for high-valued utilization of tilapia bones.

A biologics manufacturing process that connects the drug substance and drug product processes into an integrated, continuous process.

The invention discloses an application of pulsatilla saponin A3 in inhibiting the growth of multi-drug-resistant Providencia rettgeri. According to the invention, the pulsatilla saponin A3 has good in-vitro killing effect on human-derived Providencia rettgeriis with resistance to ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, tobramycin, piperacillin tazobactam,ciprofloxacin, levofloxacin, amikacin, compound phenoxymine, cefepime, ertapenem, imipenem, aztreonam and gentamicin, can inhibit in-vitro growth of the multi-drug-resistant Providencia rettgeri, andhas a minimum inhibitory concentration of 125 [mu]g/mL and a minimum bactericidal concentration of 250 [mu]g/mL. The pulsatilla saponin A3 provided by the ivnention has an antibacterial effect on themulti-drug-resistant Providencia rettgeri, can relieve or solve the problem that the drug resistance of the multi-drug-resistant Providencia rettgeri is increased, and provides a theoretical basis forclinical antibacterial treatment and novel drug research and development.

The invention relates to the technical field of medicine preparation, and particularly relates to compound amoxicillin soluble powder and a preparation method thereof. The compound amoxicillin soluble powder provided by the invention is prepared from the following ingredients including amoxicillin trihydrate, clavulanate potassium, surfactants, pH regulators, protection agents and filling agents. The amoxicillin soluble powder provided by the invention has the advantages that the solubility in water is high; the degradation cannot easily occur; and the clinic medicine effect exertion is favorably improved. The preparation method provided by the invention has the advantages that the steps are simple; the operation is easy; and the industrial production can be easily performed.

The method of synthesizing antimicrobial silver nanoparticles using pigeon dung includes collecting pigeon dung and suspending the pigeon dung in water to produce a pigeon dung aqueous extract, filtering the pigeon dung aqueous extract, adding a solution including a silver source to the pigeon dung aqueous extract to produce a mixture, and resting the mixture to allow silver nanoparticles to form. In an embodiment the antimicrobial pigeon dung nanoparticles may be incorporated in a pharmaceutical composition.

The invention discloses a ferulic acid derivative as well as a preparation method and application thereof, and belongs to the technical field of medicine research. The target ferulic acid derivative is prepared by acylating chlorination of ferulic acid and further esterification condensation with a serine derivative and lipoic acid condensation product. Wherein the used lipoic acid can eliminate free radicals for accelerating aging and pathopoiesis; the lipoic acid has the characteristics of fat solubility and water solubility, so that the lipoic acid can pass through the whole body, can reach any cell part, and provides comprehensive efficacy for a human body; meanwhile, serine is adopted as a linking part of ferulic acid and lipoic acid, the chiral structure of the serine is utilized, so that the compound has better targeting property, and the serine is a safe substance after in-vivo degradation and has better safety in vivo; the prepared ferulic acid derivative has the characteristics of good nephritis curative effect, high activity, low toxicity to other organs, good druggability and the like.

The invention relates to an artificial vitreous humor composition comprising a phosphate buffer, wherein the phosphate buffer has a pH value in the range from 7.0 to 7.7, particularly from 7.1 to 7.6, more particularly from 7.2 to 7.5. The invention further relates to a method of production of an artificial vitreous humor composition, a method for analyzing the behavior of a substance, a method for analyzing the change of the artificial vitreous humor composition upon contact with a substance and a kit of parts.

The invention discloses a fipronil and methoprene dihydric alcohol plastid, and a preparation method and application thereof. An insect repellent preparation is prepared from the following components:fipronil, methoprene, dipalmitoyl phosphatidyl choline, dihydric alcohol (including ethyl alcohol and propylene glycol), lauryl sodium sulfate and a phosphate buffer solution with the pH being 6.5. Through animal experiments, it is confirmed that the fipronil and methoprene dihydric alcohol plastid preparation has the effect of resisting dog and cat ectoparasitic infection. Relative to a fiproniland methoprene compound transdermal agent, the prepared new fipronil and methoprene dihydric alcohol plastid preparation significantly reduces toxicity and has good skin permeability, drugs reach thelong effective effect time, the insect repellent effect of the preparation is enhanced, and the action time of the preparation is prolonged.

Topical medicaments for the treatment of mammalian skin are provided, which include an actives fraction and a carrier fraction; the actives fraction comprises individual amounts of turmeric, Peganum harmala, and Arum palaestinum. In other embodiments, the actives fraction includes additional ingredients, including Vitamin C, β-sitosterol, and vanillin compound(s). The medicaments are useful in the treatment of a wide variety of conditions.

The invention relates to a microneedle for treating leucoderma as well as a preparation method and application thereof, and relates to the field of medical biological materials. The microneedle comprises hydrogel, a water-soluble substrate material and an active pharmaceutical ingredient, the active pharmaceutical ingredient is selected from at least one of the following raw materials: melanotropin, tofacitinib, tacrolimus, pimerolimus or ruxolitinib. According to the microneedle, hydrogel with high mechanical strength is adopted, the microneedle can pierce the cuticle, the hydrogel is insoluble in water, the prepared microneedle does not need a large amount of organic solvent, after the microneedle pierces the cuticle, the medicine for treating leucoderma is directly delivered to the epidermal layer and the corium layer through the diffusion effect, and the medicine application effect is enhanced; meanwhile, the substrate of the microneedle is made of a water-soluble substrate material, after the skin is punctured by the microneedle, water is absorbed, the tip of the microneedle and the substrate of the microneedle are automatically separated, and the tip which is insoluble in water is remained in the skin, so that active pharmaceutical ingredients attached to the microneedle are released in a long-acting manner, and the administration frequency is reduced.

The invention relates to a lyotropic liquid crystal precursor as well as a preparation method and application thereof. The lyotropic liquid crystal precursor is prepared from the following raw materials: a lipid matrix, a cosolvent, and aqueous hyaluronic acid particles; the mass ratio of the lipid matrix to the cosolvent is (1.5-6) : 1; the concentration of the aqueous hyaluronic acid particles in the lyotropic liquid crystal precursor is 2-5 mg/mL; and the lipid matrix is at least one selected from glyceryl monooleate, phytantriol, phospholipid, glyceryl monopalmitoleate and linoleic acid monoglyceride. The lyotropic liquid crystal precursor can be used as a carrier for delivering drugs in an articular cavity, and used for delivering drugs for treating osteoarthritis or repairing cartilage injury. Being used as a carrier for delivering drugs in the articular cavity, the lyotropic liquid crystal precursor has the advantages of being capable of buffering joint oscillation, absorbing joint stress, protecting structure and function of articular cartilage, slowly releasing drugs and the like, thereby remarkably improving treatment effects of the drugs.

The invention discloses a Chinese and western medicine composition. The composition is prepared from the following components in parts by weight: 0.5 to 2 parts of metformin preparation containing 0.5 g of medicinal components, 5 to 20 parts of radix scutellariae, 5 to 20 parts of radix paeoniae alba, 5 to 15 parts of honey-fried licorice root and 5 to 15 parts of fructus ziziphi jujubae. The invention further provides a method for preparing the traditional Chinese medicine compound through decoction extraction and then combining the traditional Chinese medicine compound with the metformin preparation, application of the Chinese and western medicine composition in preparation of medicine for treating type 2 diabetes mellitus. The invention has the advantages that the blood glucose reducing effect of the Chinese and western medicine composition is improved by taking the common target of intestinal flora as an entry point and aiming at patients who are ineffective in reducing blood glucose by oral administration of metformin clinically.

The invention relates to substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol compounds, their synthesis, pharmaceutical compositions containing them, and methods of using them in the treatment of disorders benefiting from inhibition of vesicular monoamine transporter 2 (VMAT2).